Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Upsher-Smith Laboratories, has announced the launch of Testosterone Gel (1%), the generic of the newly Food and Drug Administration (FDA) approved Vogelxo (testosterone) gel 1%, for topical use, CIII, and the first and only available generic testosterone replacement therapy (TRT) available in three convenient configurations.
Subscribe to our email newsletter
Testosterone Gel (1%) offers once-daily dosing, 24-hour coverage and three configurations: unit-dose tubes and packets and metered-dose pumps. Vogelxo and Testosterone Gel are a prescription medicine that contains testosterone.
Vogelxo and Testosterone Gel are used to treat adult males who have low or no testosterone and with conditions associated with low or no testosterone.
It is not known if Vogelxo and Testosterone Gel are safe or effective in children younger than 18 years old. Improper use of Vogelxo or Testosterone Gel may affect bone growth.
"At Upsher-Smith, we focus on driving measurable value, in dollars and outcomes, within the healthcare system. The generic availability of Testosterone Gel in three convenient configurations is an important advance in the testosterone replacement therapy marketplace and should greatly increase access for the patients who need it," said Mark Evenstad, President and Chief Executive Officer of Upsher-Smith.
According to the American Urological Association, 39 percent of men over the age of 45 have low testosterone, but few are being treated.1,2 Methods of treatment vary in cost and convenience.
Among them are injections, patches and gels. Testosterone Gel (1%) is supplied as unit-dose tubes and packets and metered-dose pumps. Each tube or packet contains 50 mg of testosterone in 5 g of gel. Each metered-dose pump delivers 12.5 mg of testosterone per complete pump actuation.